Eduardo J Medina Youssef M Zohdy Edoardo Porto Juan M Revuelta Barbero David Bray Justin Maldonado Alejandra Rodas Miguel Mayol Bryan Morales Stewart Neill William Read Gustavo Pradilla Adriana Ioachimescu Tomas Garzon-Muvdi
10.3389/fendo.2023.1195792
Front Endocrinol (Lausanne)
2023 Jul 17;14:1195792.
aggressive atypical molecular biomarkers pazopanib prolactinoma pituitary adenomas
CC BY
https://pubmed.ncbi.nlm.nih.gov/37529607/
Pituitary Neoplasms / drug therapy Pituitary Neoplasms / genetics Pituitary Neoplasms / metabolism Prolactinoma / drug therapy Prolactinoma / genetics Prolactinoma / metabolism
Pituitary Neoplasms / drug therapy Pituitary Neoplasms / genetics Pituitary Neoplasms / metabolism Prolactinoma / drug therapy Prolactinoma / genetics Prolactinoma / metabolism Case Reports Review Humans Indazoles / therapeutic use Male Middle Aged POU Domain Factors pazopanib 1-hexadecyl-2-acetyl-glycero-3-phosphocholine Indazoles POU6F2 protein, human POU Domain Factors
PMC10388536
37529607
Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas
2023